Publications by authors named "Elisa Bossi"

Claim this Profile
A
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.
Federica Malighetti, Matteo Villa, Mario Mauri, Simone Piane, Valentina Crippa, Elisa Bossi

Biomedicines· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Andrea Aroldi, Mario Mauri, Daniele Ramazzotti, Matteo Villa, Federica Malighetti, Elisa Bossi

J Cell Mol Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Elisa Bossi

Hemasphere· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas.
Giovanni Rindone, Andrea Aroldi, Elisa Bossi, Luisa Verga, Giovanni Zambrotta

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).
Elisa Bossi, Andrea Aroldi, Lorenza Maria Borin, Luisa Verga, Diletta Fontana

EJHaem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, Roberto Latagliata, Mario Tiribelli, Elisa Bossi

Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Elisa Bossi, Andrea Aroldi, Filippo A Brioschi, Carolina Steidl, Silvia Baretta

Am J Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Imatinib-non-responsive patient with an Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization.
Ilaria Crespiatico, Elisa Bossi, Filippo Brioschi, Rocco Piazza, Luca Mologni

Clin Case Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis